Log in to search using one of your social media accounts:

 

Pulmonary Hypertension in ARDS: Inflammation Matters! Pulmonary Hypertension in ARDS: Inflammation Matters!
This editorial discusses the significance of inflammation in the pathogenesis of pulmonary hypertension in acute respiratory distress syndrome.Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide
Bellerophon Therapeutics (NSDQ:BLPH) touted data today from a Phase II trial of pulsed, inhaled nitric oxide in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease. The 10-patient trial was designed to evaluate the effects of pulsed, inhaled nitric oxide on targeted vasodilation and the chronic effect on hemodynamics and exercise capacity. Get the full story at our sister site, Drug Delivery Business News. The post Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Bellerophon Therapeutics Source Type: news

Pulmonary hypertension cure? This could treat high blood pressure affecting LUNGS
PULMONARY arterial hypertension is caused by changes to the pulmonary arteries - the blood vessels that carry blood from the heart to the lungs. (Source: Daily Express - Health)
Source: Daily Express - Health - September 1, 2017 Category: Consumer Health News Source Type: news

Study: Viagra may harm, not help, patients with heart valve disorder
New research suggests Viagra (sildenafil) might raise patients' risk of " pulmonary hypertension linked to valvular heart disease. " (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 30, 2017 Category: Consumer Health News Source Type: news

Sildenafil Warning in Pulmonary Hypertension After Valve Surgery Sildenafil Warning in Pulmonary Hypertension After Valve Surgery
Clinicians should not assume that sildenafil is beneficial in pulmonary hypertension following valve surgery, warn Spanish researchers after finding the drug doubles clinical events in these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Sildenafil should be avoided in valve disease with residual pulmonary hypertension
(European Society of Cardiology) Sildenafil should not be used to treat residual hypertension in patients with valvular heart disease, according to late-breaking results from the SIOVAC trial presented today in a Hot Line LBCT Session at ESC Congress. The off-label use of the drug led to worse clinical outcomes including a doubled risk of hospitalization compared to placebo. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Ventripoint touts publication of VMS heart analysis system study
Ventripoint Diagnostics this week announced the publication of a study of its VMS heart analysis system, touting that the system’s functionality. The study, undertaken by the cardiology group at London’s Royal Free Hospital, was published in the journal Echocardiography. Results from the study indicate that the system was able to follow patients with enlarged right ventricles and accurately measure small but significant changes in volume and function, Ventripoint said. The company said that the system’s ability to monitor clinical outcomes after therapy has been initiated is important in determining if th...
Source: Mass Device - August 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials VentriPoint Diagnostics Source Type: news

At What Height Do You Consider Preventative Treatment for Acute Mountain Sickness?
Discussion Acute mountain sickness (AMS) is a well-known problem for some people who travel to high altitude, especially altitudes> 2500 m (~8200 feet). Symptoms include headache, nausea or emesis, shortness of breath, dizziness, fatigue, difficulty sleeping and poor appetite. The incidence in adults ranges from 25% at 2975 m to up to 75% at 5896 m. The incidence in children is less clear but it appears that children are more susceptible at 45% for 16-19 year olds for similar altitudes. Risk factors are numerous including age, gender, obesity, ascent rate, altitude for sleeping, previous exposure to high altitude, previ...
Source: PediatricEducation.org - August 21, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD
The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies
[12-14-2011] The U.S. Food and Drug Administration (FDA) is updating the public on the use of selective serotonin reuptake inhibitor (SSRI) antidepressants by women during pregnancy and the potential risk of a rare heart and lung condition known as persistent pulmonary hypertension of the newborn (PPHN). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

Mallinckrodt ’s Phase IV registry for PPHN medicine starts enrolment
Mallinckrodt Pharmaceuticals has started patient enrolment in a Phase IV registry (PaTTerN) to evaluate INOMAX (nitric oxide) gas inhalation to treat persistent pulmonary hypertension of the newborn (PPHN). (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2017 Category: Pharmaceuticals Source Type: news

Mallinckrodt enrolls first infant in registry for inhaled nitric oxide gas
Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that it included the first patient in its Phase IV registry evaluating the use of inhaled Inomax nitric oxide gas for premature neonates compared to term and near-term newborns. Inomax, which has FDA approval, is designed to boost oxygenation and lessen the need for extracorporeal membrane oxygenation in term and near-term neonates with hypoxic respiratory failure linked to pulmonary hypertension. Get the full story at our sister site, Drug Delivery Business News. The post Mallinckrodt enrolls first infant in registry for inhaled nitric oxide gas appeared first on Mas...
Source: Mass Device - August 1, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pediatrics Pharmaceuticals Wall Street Beat Mallinckrodt Source Type: news

Pulmonary Hypertension (Symptoms, Treatment Medications, Life Expectancy)
Title: Pulmonary Hypertension (Symptoms, Treatment Medications, Life Expectancy)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/26/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - July 26, 2017 Category: Respiratory Medicine Source Type: news

Clinical Trial Saves Baby ’s Lungs
Treatment TermsChildren's health CategoriesClinical trialsFamily health TagsPatient story Sub-Title Baby Collier Proves He ’s a Survivor Author Burgetta Wheeler Overview Collier Hart sat smiling in his crib repeatedly saying, “Wa wa.” Given a sippy cup of water, he threw back his head and drained it. He put his hands together, fingertips touching, and made the sign for “more.” None of this is unusual for a 2-year-old, but it is for Collier. He spent the first 15 months of his life at Duke Children’s Hospital af ter being born with severely underdeveloped lungs. Hero Imageco...
Source: dukehealth.org: Health Tips - June 23, 2017 Category: Primary Care Authors: klh85 at duke.edu Source Type: news

Macitentan Viable for Inoperable Pulmonary Hypertension Macitentan Viable for Inoperable Pulmonary Hypertension
An endothelin receptor antagonist is showing promise in the phase 2 MERIT study of patients with chronic thromboembolic pulmonary hypertension, who have few treatment options.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 24, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

TrumpCare And My Daughter's Wheelchair
When a child is born ill or with disabilities, there is love, but there is also fear. Fear of what will happen during the endless medical procedures, what kind life the child might live, how life will be different than what was imagined and fear of paying for it all. When my daughter Claire was born almost 11 years ago, her health and future were uncertain. Born with a rare genetic disorder that affects nearly every part of her body, Claire spent time in the neo-natal intensive care unit, had heart surgery when she was 4 months old, and endured test after test after test to figure out the extent of the impact of her extra ...
Source: Healthy Living - The Huffington Post - May 22, 2017 Category: Consumer Health News Source Type: news

My 11-Year-Old Daughter’s Life Depends On Medicaid
When a child is born ill or with disabilities, there is love, but there is also fear. Fear of what will happen during the endless medical procedures, what kind life the child might live, how life will be different than what was imagined and fear of paying for it all. When my daughter Claire was born almost 11 years ago, her health and future were uncertain. Born with a rare genetic disorder that affects nearly every part of her body, Claire spent time in the neo-natal intensive care unit, had heart surgery when she was 4 months old, and endured test after test after test to figure out the extent of the impact of her extra ...
Source: Healthy Living - The Huffington Post - May 22, 2017 Category: Consumer Health News Source Type: news

United Therapeutics reworks deal ahead of a key patent's expiration
Silver Spring drugmaker United Therapeutics Corp. extended an exclusive license with drug giant Eli Lilly& Co. to cover its pulmonary hypertension drug Adcirca, which will lose part of its patent protection later this year. The active ingredient in Adcirca is tadalafil, also the active pharmaceutical ingredient in Cialis, which is marketed by Eli Lilly (NYSE: LLY) to treat erectile dysfunction. United Therapeutics (NASDAQ: UTHR), in 2008, acquired the commercial rights to Adcirca from Eli Lilly… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 19, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Options Emerging for Pulmonary Hypertension, Chronic Cough Options Emerging for Pulmonary Hypertension, Chronic Cough
Results from the MERIT study evaluating macitentan in pulmonary hypertension will be presented at the American Thoracic Society Conference, along with a study of a P2X3 antagonist for chronic cough.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Local research economy stands to lose plenty from possible NIH cuts
It was a young woman with a rare and devastating disease that spurred Dr. Raymond Benza to new heights in his personal research. It also found him at the top of some of the world’s tallest mountains, from Kilimanjaro to the Grand Tetons, breathing hard in the thin air as his lungs worked overtime to oxygenate his blood. That struggle to breathe that many mountain climbers face thousands of feet above sea level closely mim ics pulmonary hypertension, the life-threatening condition Benza has devoted… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 12, 2017 Category: American Health Authors: Lydia Nuzum Source Type: news

Recomendaciones del VI Consenso Clinico de SIBEN para la Hipertension Pulmonar Persistente del Recien Nacido
This article summarizes the recommendations of the 6th Clinical Consensus on Persistent Pulmonary Hypertension of the Newborn of the Ibero-American Society of Neonatology (SIBEN). It describes the etiology, pathophysiology, and treatment (including maintaining the optimal oxygenation, alveolar ventilation, optimal perfusion, and use of pulmonary vasodilators, such as inhaled nitric oxide and sildenafil, as well as emerging therapies). It ends with a summary of the SIBEN consensus clinical recommendations, as a practical way to keep improving the care of our newborns. Resumen La hipertensión pulmonar persistente del...
Source: NeoReviews recent issues - May 1, 2017 Category: Pediatrics Authors: Golombek, S., Sola, A., Lemus, L., y Miembros del Consenso de SIBEN Tags: Pediatric Drug Labeling Update Articles Source Type: news

Two Autoantibodies in SLE Predict Development of Pulmonary Hypertension (CME/CE)
(MedPage Today) -- Early biomarkers needed to identify patients at risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 28, 2017 Category: Cardiology Source Type: news

United Therapeutics partners with 3-D printer to make human organs
Silver Spring-based United Therapeutics Corp. has been clear about its ambitions to build an unlimited supply of certain transplantable organs. Now, founder Martine Rothblatt said the company's new multiyear collaboration with a 3-D bioprinting company, announced Wednesday, takes it a big step toward that goal. United Therapeutics (NASDAQ: UTHR), which now mostly develops and sells pulmonary hypertension drugs on the market, announced a development agreement to create develop "solid-organ scaffolds"… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 27, 2017 Category: Biotechnology Authors: Tina Reed Source Type: news

Respira Therapeutics Announces Collaboration with United Therapeutics to Treat Pulmonary Hypertension
Respira Therapeutics, Inc. is developing inhaled prescription pharmaceutical products employing its breakthrough high efficiency, AOS™ dry powder inhaler (DPI) technology to deliver drugs to treat pulmonary and other diseases ALBUQUERQUE, N.M., April 12... Biopharmaceuticals, Devices, Drug Delivery Respira Therapeutics, United Therapeutics, RT234, pulmonary hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 12, 2017 Category: Pharmaceuticals Source Type: news

TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Seventh national pulmonary hypertension audit
The national audit of pulmonary hypertension sets out to measure the quality of care provided to people referred to pulmonary hypertension services in England and Scotland. (Source: NHS Networks)
Source: NHS Networks - March 23, 2017 Category: UK Health Source Type: news

Your NEJM Group Today: Confusion & Epistaxis Case / End-of-Life Discussions in Primary Care / Virginia Rheumatology Opportunity (FREE)
By the Editors Here's today's offering from NEJM Group:NEJM Clinical Practice Center: Case record: A 73-year-old man with a history of heart failure, pulmonary hypertension, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 13, 2017 Category: Primary Care Source Type: news

Study supports use of PDE-5 inhibitors in pediatrics
A review of research has shown that the use of phosphodiesterase type 5, or PDE-5, inhibitors are safe for treating pulmonary hypertension in children. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 24, 2017 Category: Consumer Health News Source Type: news

Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension
(Children's National Health System) A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 inhibitors in pediatric patients with pulmonary hypertension published Feb. 24, 2017 in Pediatrics demonstrates that scientific evidence supports the use of this class of medications in infants, neonates and children with pulmonary hypertension. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 24, 2017 Category: Global & Universal Source Type: news

Atrial Septostomy and Targeted Therapy in PH With NF1 Atrial Septostomy and Targeted Therapy in PH With NF1
The combination of atrial septostomy with targeted therapy may be an effective approach in the treatment of neurofibromatosis complicated by pulmonary hypertension.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

J & J, Actelion still in talks despite Opsumit failure
Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart defects and pulmonary hypertension. Get the full story at our sister site, Drug Delivery Business News. The post J&J, Actelion still in talks despite Opsumit failure appeared first on ...
Source: Mass Device - January 23, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Mergers & Acquisitions Respiratory Wall Street Beat Actelion Pharmaceuticals Johnson & Johnson Source Type: news

This Lung Disorder Tends To Be Misdiagnosed In Many Adults
(Reuters Health) ― As many as one in three adults diagnosed with asthma may not actually have the chronic lung disorder, a Canadian study suggests. Researchers did lung function tests on 613 adults who had been diagnosed with asthma within the past five years. If participants took asthma medicines, researchers gradually weaned them off the drugs over four clinic visits to see how well their lungs worked without treatment. The evaluations ruled out asthma in 203 of the participants, or 33 percent. After one year of follow-up, 181 of these people still did too well on lung tests to be diagnosed with asthma, researchers rep...
Source: Healthy Living - The Huffington Post - January 18, 2017 Category: Consumer Health News Source Type: news

This Lung Disorder Tends To Be Misdiagnosed In Many Adults
(Reuters Health) ― As many as one in three adults diagnosed with asthma may not actually have the chronic lung disorder, a Canadian study suggests. Researchers did lung function tests on 613 adults who had been diagnosed with asthma within the past five years. If participants took asthma medicines, researchers gradually weaned them off the drugs over four clinic visits to see how well their lungs worked without treatment. The evaluations ruled out asthma in 203 of the participants, or 33 percent. After one year of follow-up, 181 of these people still did too well on lung tests to be diagnosed with asthma, researchers rep...
Source: Science - The Huffington Post - January 18, 2017 Category: Science Source Type: news

Rahaghi Wins ATS Foundation/Pulmonary Hypertension Association Award
Farbod Rahaghi, MD, PhD, of the Division of Pulmonary and Critical Care Medicine, has been awarded a two-year, $40,000 annual grant from the American Thoracic Society (ATS) Foundation ’s Research Program and the Pulmonary Hypertension Association for (Source: BWH News)
Source: BWH News - January 17, 2017 Category: Hospital Management Source Type: news

Cochrane Priority Reviews List: December 2016 Update
Cochrane-wide prioritisation remains an important project, with over 140 priority reviews or updates have been published since it began in January 2015.The December 2016 revision of the Cochrane Priority Reviews List includes new titles from the Cochrane Airways, Anaesthesia, Dementia& Cognitive Improvement, ENT, Epilepsy, Gynaecological, Neuro-oncology and Orphan Cancers, Gynaecology& Fertility, Haematological Malignancies, Heart, Incontinence, Kidney& Transplant, Lung Cancer, Neuromuscular Disease, Oral Health, Skin, Stroke, and Urology Groups.The following titles on the list are open to new authors:Long-acti...
Source: Cochrane News and Events - December 14, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Cochrane Priority Reviews List: Update
February 2017 UpdateThe February 2017 revision of the Cochrane Priority Reviews List includes new titles from the Cochrane Acute Respiratory Infections, Cystic Fibrosis& Genetic Disorders, ENT, Musculoskeletal, and Wounds Groups.The following titles on the list are open to new authors:Biomarkers for predicting outcomes in endometrial cancer (Gynaecological, Neuro-oncology and Orphan Cancer)Diagnostic test accuracy of sentinel LN node sampling in endometrial cancer (Gynaecological, Neuro-oncology and Orphan Cancer)Immunomodulatory treatment for amyotrophic lateral sclerosis /motor neuron disease (ALS/MND) (Neuromuscular...
Source: Cochrane News and Events - December 14, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Breathing easier for pulmonary hypertension patients
It was two years ago, on Christmas Day 2014,?when Orlando, Florida resident Laura Floeckher, 47, was diagnosed with?pulmonary hypertension (PH), a?rare disorder of the lungs affecting about 30 in every one million people. Mayo Clinic in Florida is one of 26 designated Pulmonary Hypertension and Vascular Disease Centers?in the country, recognized for its comprehensive care, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 11, 2016 Category: Databases & Libraries Source Type: news

Congenital Diaphragmatic Hernia: Maximizing Survival
Congenital diaphragmatic hernia occurs when a portion of the fetal diaphragm is absent, allowing abdominal contents to enter the thorax, and is associated with impaired pulmonary development. Although overall mortality is near 30%, a mortality rate less than 15% may be possible by following a standardized multidisciplinary care plan. Fetal diagnosis and evaluation can improve coordination of care, but there is no clear role for fetal intervention. After birth, gentle ventilation with permissive hypercapnia supports the infant while minimizing lung injury. Appropriate cardiovascular support, treatment of pulmonary hypertens...
Source: NeoReviews recent issues - November 30, 2016 Category: Pediatrics Authors: Weems, M. F., Jancelewicz, T., Sandhu, H. S. Tags: Pediatric Drug Labeling Update Articles Source Type: news

Mom Captures Beautiful Moment ‘Miracle' Baby Sees Snow For The First Time
In December 2015, doctors told Johanna Morton she was going to miscarry. Just a few weeks ago, she watched her daughter see snow for the first time.  Morton told The Huffington Post that when she was 12 weeks pregnant, doctors discovered something was wrong with her baby’s heart based on the way it sounded.   “They told me I was going to miscarry,” Morton said. “A week or two after when I didn’t miscarry, it seemed like every appointment we would be told something else was wrong with her heart, another diagnosis.” Doctors later told Morton that her baby would be stillborn. Her ...
Source: Healthy Living - The Huffington Post - November 28, 2016 Category: Consumer Health News Source Type: news

Mayo Clinic Minute: Under pressure with pulmonary hypertension
November is Pulmonary Hypertension Awareness Month. Pulmonary hypertension?is a disease that, because of its name, sometimes is confused with high blood pressure. But, pulmonary hypertension?is different. Mayo Clinic pulmonologist Dr. Charles Burger says pulmonary hypertension?means the pressures inside the lung are elevated, forcing the right side of the heart to work harder to increase blood [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 15, 2016 Category: Databases & Libraries Source Type: news

Actelion reports positive Merit study results of macitentan to treat pulmonary hypertension
Swiss bio-technology company Actelion has reported positive results from its macitentan in the treatment of Inoperable chronic thromboembolic pulmonary hypertension (Merit) study of macitentan in patients with inoperable chronic thromboembolic pulmon … (Source: Drug Development Technology)
Source: Drug Development Technology - November 8, 2016 Category: Pharmaceuticals Source Type: news

Pretreating red blood cells with nitric oxide may reduce side effect linked to transfusions
A new treatment may diminish a dangerous side effect associated with transfusions of red blood cells (RBCs) known as pulmonary hypertension, an elevated blood pressure in the lungs and heart that can lead to heart failure, suggests a new study. The treatment involves exposing RBCs that have been collected, processed and stored for transfusion to the gas, nitric oxide. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 7, 2016 Category: Science Source Type: news

Pretreating red blood cells with nitric oxide may reduce side effect linked to transfusions
(American Society of Anesthesiologists) A new treatment may diminish a dangerous side effect associated with transfusions of red blood cells (RBCs) known as pulmonary hypertension, an elevated blood pressure in the lungs and heart that can lead to heart failure, suggests a new study published in the November issue of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2016 Category: Global & Universal Source Type: news

Mast Therapeutics touts interim data from pulmonary hypertension study
Mast Therapeutics (NYSE:MSTX) touted interim data from a Phase II study of its AIR001 candidate in patients with pulmonary hypertension (PH) and PH associated with heart failure with preserved ejection fraction. Positive interim results from the ongoing trial were published in the Journal of Clinical Investigation. The San Diego-based company enrolled 50 patients to study its nebulized inhaled nitrite and interim results showed that AIR001 significantly decreased pulmonary, right atrial and pulmonary capillary wedge pressures. The change was most prominent in patients with PH associated with heart failure with pr...
Source: Mass Device - November 4, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Mast Therapeutics Source Type: news

UCLA lung transplant program performs landmark 1000th surgery
TheUCLA Lung Transplant program performed its 1,000th transplant surgery in mid-September, becoming the first program on the West Coast, and one of only seven centers nationwide, to achieve this milestone.The recipient of the donor lungs was Elba De Contreras, 59, from Goleta, California, who suffered from idiopathic pulmonary fibrosis and pulmonary hypertension. The six-hour surgery took place at Ronald Reagan UCLA Medical Center, led by Dr. Abbas Ardehali, surgical director of the lung and heart transplant programs.De Contreras, who relied on an oxygen tank prior to her surgery, is recuperating well and said she feels ha...
Source: UCLA Newsroom: Health Sciences - October 4, 2016 Category: Universities & Medical Training Source Type: news

UCLA lung transplant program performs landmark 1,000th surgery
TheUCLA Lung Transplant program performed its 1,000th transplant surgery in mid-September, becoming the first program on the West Coast, and one of only seven centers nationwide, to achieve this milestone.The recipient of the donor lungs was Elba De Contreras, 59, from Goleta, California, who suffered from idiopathic pulmonary fibrosis and pulmonary hypertension. The six-hour surgery took place at Ronald Reagan UCLA Medical Center, led by Dr. Abbas Ardehali, surgical director of the lung and heart transplant programs.De Contreras, who relied on an oxygen tank prior to her surgery, is recuperating well and said she feels ha...
Source: UCLA Newsroom: Health Sciences - October 4, 2016 Category: Universities & Medical Training Source Type: news

Genetically modified probiotic may treat pulmonary hypertension
Stephen FellerORLANDO, Fla., Sept. 15 (UPI) -- Genetically modifying a probiotic may open a new method for treating pulmonary hypertension, according to recent animal experiments. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 15, 2016 Category: Consumer Health News Source Type: news

Weight Loss Pills And Products Don't Work And Aren't Safe
Our ancestors lived in a feast or famine world. When you don't know where your next meal is coming from, or when it will arrive, the smart play is to pig out every time food is available. Our genes are programmed to extract as much energy as possible from what we eat and to store any extra energy in fat reservoirs, available in reserve for future famines. These deeply ingrained genetic tendencies worked great in the austere world of our ancestors, but are a disaster in our current world of refrigerators, ubiquitous fast food joints and milk shakes. Only one third of Americans are now able to maintain a normal weight; one ...
Source: Science - The Huffington Post - September 5, 2016 Category: Science Source Type: news

Vascular Stiffness Drives Pulmonary Hypertension Processes Vascular Stiffness Drives Pulmonary Hypertension Processes
Extracellular matrix (ECM) stiffening underlies mechanoactivation of the transcriptional coactivators YAP and TAZ which in turn drive aspects of pulmonary hypertension (PH), according to in vitro and animal studies.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2016 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Saving six: Life before and after transplant
An organ transplant is a life-changing event extending far beyond the operating room, the clinics and the hospital walls. Read about five children, one young adult and their families, whose lives were forever changed by the Pediatric Transplant Center at Boston Children’s Hospital. Lydia’s liver transplant, a mom’s gift Dawn Cavanagh gave her daughter life twice — first when she was born and, again, when she gave 13-year-old Lydia a piece of her liver last summer. The donor-approval process, which occurs with Boston Children’s partner Lahey Hospital & Medical Center, required hours o...
Source: Thrive, Children's Hospital Boston - August 31, 2016 Category: Pediatrics Authors: Emily Williams Tags: Our Patients’ Stories double lung transplant ECMO heart failure heart transplant Heart transplant program heart-lung transplant Heung Bae Kim Intestine and Multivisceral Transplant Program Khashayar Vakili kidney transplant Kidney Source Type: news